

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1.449A/P.T.O.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	09/896,811
Filing Date	June 29, 2001
First Named Inventor	Madden, Thomas D., et. al
Art Unit	1614
Examiner Name	Clinton T. Ostrup
Attorney Docket Number	16303-008020

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
CPO	4	PC	WO 95/08986	A1	04/06/1995			<input type="checkbox"/>
	5	PC	WO 98/17256	A1	04/30/1998			<input type="checkbox"/>
	6	PC	WO 99/13816	A2	03/25/1999			<input type="checkbox"/>
	7	PC	WO 99/51202	A2	10/14/1999			<input type="checkbox"/>
CPO	8	PC	WO 00/23052	A1	04/27/2000			<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner
Signature

Date
Considered

4/13/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231

WC 9047788 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/896,811
		Filing Date	June 29, 2001
		First Named Inventor	Madden, Thomas D., et. al.
		Art Unit	1614
		Examiner Name	Clinton T. Ostrup
Sheet 2	of 3	Attorney Docket Number	16303-008020

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CTO	9	BURRIS III, et al., <i>J. Natl. Cancer Inst.</i> , 84:1816-1820 (1992)	
	10	CLEMENTS, et al., <i>Cancer Chemother. Pharmacol.</i> , 44:411-416 (1999)	
	11	EMERSON, et al., <i>Cancer Res.</i> , 55:603-609 (1995)	
	12	ERICKSON-MILLER, et al., <i>Cancer Chemother. Pharmacol.</i> , 39:467-472 (1997)	
	13	GROCHOW, et al., <i>Drug. Metab. Dispos.</i> , 20(5):706-713 (1992)	
	14	HARDMAN, et al., <i>Anticancer Res.</i> , 19:2269-2274 (1999)	
	15	HSIANG, et al., <i>Cancer Res.</i> , 48:1722-1726 (1988)	
	16	MADDEN, et al., <i>Chem. Phys. Lipids</i> , 53:37-46 (1990)	
	17	MADDEN, et al., "Encapsulation of topotecan in lipid-based carrier systems. Evaluation of drug stability and plasma elimination in a murine model, and comparison of antitumor efficacy against murine L1210 and B16 tumors," <i>Proc. of ASCO</i> , 17:abstract #754 (1998)	
	18	MAYER, et al., <i>Biochim. Biophys. Acta</i> , 1025:143-151 (1990)	
	19	MCCABE, et al., <i>Cancer Invest.</i> , 12(3):308-313 (1994)	
	20	O'LEARY, et al., <i>Clin. Cancer Res.</i> , 5:181-187 (1999)	
CTO	21	ORMROD, et al., <i>Drugs</i> , 58(3):533-551 (1999)	
	22	TARDI, et al., <i>Cancer Res.</i> , 60:3389-3393 (2000)	

Examiner Signature		Date Considered	11/13/03
-----------------------	--	--------------------	----------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9047788 v1

JAN 27 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/896,811
Filing Date	June 29, 2001
First Named Inventor	Madden, Thomas D., et. al.
Art Unit	1614
Examiner Name	Clinton T. Ostrup
Attorney Docket Number	16303-008020

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CTO	23	THOMPSON, <i>Biochim. Biophys. Acta</i> , 1400:301-319 (1998)	
CTO	24	WALL, et al., <i>J. Am. Chem. Soc.</i> , 88:3888-3890 (1966)	

Examiner
Signature



Date
Considered

11/13/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9047788 v1